PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22868830-13	2013	Upregulation of ApN by Rimonabant was unaltered by inhibiting cAMP production.	Rimonabant	23-33	adiponectin, C1Q and collagen domain containing	Homo sapiens	16-19	
22087859-14	2011	Moreover, SR141716A restored adiponectin secretion to normal levels after LPS treatment.	Rimonabant	10-19	adiponectin, C1Q and collagen domain containing	Homo sapiens	29-40	
19112166-7	2009	Rimonabant 20 mg produced significantly greater changes from baseline versus placebo in HDL-C (+7.4%) and TG levels (-18%; P<0.0001), as well as low-density lipoprotein (LDL) and HDL particle sizes, apolipoprotein A1 and B, HDL2, HDL3, C-reactive protein, and adiponectin levels (all P<0.05).	Rimonabant	0-10	adiponectin, C1Q and collagen domain containing	Homo sapiens	263-274	
20415685-9	2010	Weight loss, through diet, lifestyle changes and/or medications including orlistat, sibutramine, rimonabant or bariatric surgery, increase adiponectin and may improve liver histology.	Rimonabant	97-107	adiponectin, C1Q and collagen domain containing	Homo sapiens	139-150	
21198716-11	2011	In addition, patients treated with 20 mg rimonabant daily exhibited increase in adiponectin.	Rimonabant	41-51	adiponectin, C1Q and collagen domain containing	Homo sapiens	80-91	
19199981-6	2009	Randomized trials of rimonabant in patients with overweight or obesity and/or type 2 diabetes have demonstrated marked and significant improvements in body weight, waist circumference, glycemic control (in patients with type 2 diabetes), features of atherogenic dyslipidemia, insulin resistance, adipose tissue-derived cytokines (leptin and adiponectin) and C-reactive protein (a marker of systemic inflammation).	Rimonabant	21-31	adiponectin, C1Q and collagen domain containing	Homo sapiens	341-352	
18951999-3	2009	Rimonabant, an antiobesity drug, presents a dual effect by decreasing food intake and importantly increasing adiponectin.	Rimonabant	0-10	adiponectin, C1Q and collagen domain containing	Homo sapiens	109-120	
17392496-3	2007	Treatment with rimonabant was also associated with other favorable changes, including better glycemic control in type 2 diabetes mellitus, improved lipid profile, reduced blood pressure, increased adiponectin levels, fall in high-sensitivity C-reactive protein concentrations, and an overall decrease in the prevalence of the metabolic syndrome.	Rimonabant	15-25	adiponectin, C1Q and collagen domain containing	Homo sapiens	197-208	
18542014-4	2008	Rimonabant, the first selective cannabinoid 1 receptor blocker in clinical use, has been shown to reduce body weight, waist circumference, glycated haemoglobin, triglycerides, insulin resistance index, and to increase HDL cholesterol and adiponectin concentrations in patients with type 2 diabetes, confirming data on nondiabetic overweight/obese patients.	Rimonabant	0-10	adiponectin, C1Q and collagen domain containing	Homo sapiens	238-249	
18426513-3	2008	Adiponectin levels were increased, an effect that correlated with HDL cholesterol augmentation, while small dense LDL cholesterol levels were decreased in patients receiving rimonabant 20 mg compared with those receiving placebo in RIO Lipids.	Rimonabant	174-184	adiponectin, C1Q and collagen domain containing	Homo sapiens	0-11	
18154742-8	2007	In addition, rimonabant was associated with favorable changes in several other cardiometabolic risk factors, including significant increases in serum levels of high-density lipoprotein cholesterol and adiponectin, as well as reductions in serum levels of triglycerides, small, dense low-density lipoprotein particles, C-reactive protein, insulin resistance, and glycosylated hemoglobin.	Rimonabant	13-23	adiponectin, C1Q and collagen domain containing	Homo sapiens	201-212	
16291982-7	2005	Rimonabant at a dose of 20 mg also resulted in an increase in plasma adiponectin levels (repeated-measures method, 57.7 percent, and last-observation-carried-forward analyses, 46.2 percent; P<0.001), for a change that was partly independent of weight loss alone.	Rimonabant	0-10	adiponectin, C1Q and collagen domain containing	Homo sapiens	69-80	
17296341-2	2007	Numerous other metabolic changes, including reduced prevalence of the metabolic syndrome and associated cardiovascular disease (CVD) risk factors, reduced fasting glucose, and elevated adiponectin, have been demonstrated with the administration of rimonabant.	Rimonabant	248-258	adiponectin, C1Q and collagen domain containing	Homo sapiens	185-196	
17208662-10	2006	Rimonabant, a selective cannabinoid 1 receptor antagonist in Phase III studies, also has been shown to increase adiponectin levels.	Rimonabant	0-10	adiponectin, C1Q and collagen domain containing	Homo sapiens	112-123